Volume +28%, profit −7%: The margin collapse Finolex won't explain

The paradox of Finolex's Q2 is written into these four numbers. Revenue grew 27.4%, volume surged 28%—textbook operational leverage should have lifted profit. Instead, net profit fell 7%. On the call, management framed the quarter as a recovery; the numbers tell a different story. They tell a story of margin compression so acute that 28% volume growth delivered negative profit growth. That gap is not a rounding error. It is structural, it is material, and management spent the earnings call explaining it away rather than addressing it.

The company blames two things: first, inventory. Finolex procured raw materials—PVC, EDC, VCM—at elevated prices in Q1 when spot rates were volatile. That high-cost inventory was consumed (and sold) in Q2, creating a lag between what the company paid and what it could recoup from lower current-market pricing. That lag is real. But it is also temporary and, management argues, explains the margin compression. The second culprit: schemes. To maintain market share in a competitive channel environment, Finolex has been running discounts and schemes—promotional spending that doesn't show up as discrete line items but flows through gross margin and distribution costs. Neither of these is news. Both, however, suggest that the company is not defending pricing power via customer retention or brand; it is defending via promotional spend.

Add a product mix shift—volume increasingly flowing to non-agri segments (fittings up, agri down as a share) and lower-margin categories like fitting growth at 7%—and the margin story becomes clearer. This is not a quarter where the company gained pricing power. It is a quarter where the company lost margin to buy volume, and is framing the volume recovery (which is real) as the frame for the quarter.

The first claim is supported—volume did grow 28% YoY. The second is overstated. PAT fell 6.9% YoY, PBT fell 3.2% QoQ; "flatish" is not the word. The third is supported on the math—Q2 PBT margin is approximately 14%, H1 is running near 15%, and sub-15% EBITDA is achievable but tight. The fourth is supported; H1 volume is −4% YoY, meaning Q2's 28% recovery offset Q1 weakness entirely. The fifth is where the real issue sits: management claims the margin lag is temporary and inventory-driven. But inventory lag is a one-off; the schemes and promotional spending appear structural. The call offers no signal that pricing power will return when inventory clears.

On the prior call (Q1 FY-2027), management guided to sub-15% EBITDA for the year and flagged Q1 weakness from inventory overstocking and destocking recovery. This call validates that. Q2 volume bounced as destocking began, and management maintained EBITDA guidance. But the margin band has tightened: the company is now running schemes to hold share, and concedes structural dependency on promotional spend—a pivot from the prior narrative of pricing power. Capex remains undefined; the Board has not finalized the shape, timing, or deployment of the planned ₹150 Cr capex. That uncertainty is new and material. On the positive side: the company's cash position remains strong at ₹2,584 Cr, providing runway for capex or shareholder returns without external funding.

The stock is trading at ₹141.95 as of today—down 60% from its all-time high of ₹355.9, and currently below its 20-day, 50-day, and 200-day moving averages (₹145.8, ₹151.27, ₹167.25 respectively). The bearish trend is evident. On the result announcement (Oct 30, 2026), the stock popped +2.68% on day 1 and held gains to +4.95% by day 3, suggesting the market initially viewed the print as incrementally positive. However, the move has been modest and has not broken the bearish structure. Ownership shows FII at 5.85% (down 0.02pp QoQ) and DII at 11.35% (down 1.44pp QoQ)—both are trimming. Promoter holding remains stable at 52.47%. The combination of weak institutional demand, a small post-result pop that did not reverse, and the stock sitting well below key moving averages signals market skepticism. The 60% drawdown from ATH suggests the stock has already repriced for growth disappointment, but the margin compression visible in Q2 is fresh, and the modest relief-rally suggests the street is not yet convinced the margin story is over. For a holder at current prices, the risk/reward hinges on whether H2 profitability recovers.